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Abstract:
This study was designed to develop and test a system to monitor adherence with nonhormonal oral chemotherapeutic agents using an automated voice response (AVR)
system plus nursing intervention. Participants received the Symptom Management
Toolkit then participated in an interview for symptom severity, satisfaction, and beliefs
about oral agents. Patients received weekly AVR calls, which assessed adherence to
oral agents and severity of 15 symptoms. Patients who reported adherence of < 100% of
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prescribed oral agents or symptoms of 4 or greater (0-10 scale) for three consecutive
weeks, were called by a nurse for assistance with symptom management and
adherence to oral chemotherapy medications. Following the 8 weekly AVR calls,
patients participated in a follow up interview and medical record review. Subjects were
30 oncology patients who were ambulatory and treated at two cancer centers in Midwest
USA. The results indicate 23.3% non adherence rate to oral chemotherapy medications
due to symptoms and forgetting to take the medication. An association between
symptom management and adherence was found. Symptom severity and beliefs about
medications were not significantly different between adherent and non adherent patients.
This pilot study demonstrated the ability to accrue patients for a longitudinal trial and
informed intervention design, while providing guidance for future interventions and
research studies.

Background
There are relatively few studies seeking to determine if patient adherence could be
improved by reducing severity of symptoms and side effects thought to be related to
certain medications. This pilot study was guided by two questions: 1) Can patients be
monitored for adherence to oral chemotherapeutic agents and can adherence be
improved by an Automated Voice Response (AVR) system and an intervention nurse
where both address symptom management and adherence 2) Can this be demonstrated
by an observed association between symptom management and improved patient
adherence?

Objectives
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The purpose of this study was to determine whether patients with breast, colon, or lung
cancer, on non-hormonal oral chemotherapeutic agents can be monitored and receive
interventions for adherence using an AVR system and a nurse intervener.

Methods
Setting/Sample: Accrual of patients for this pilot occurred at a National Cancer Institute
Community Clinical Oncology Programs (NCI CCOP) clinical site, and a university based
cancer clinic, both located in Michigan. Subjects were entered in the study between
September 2007 and January 2008. Thirty subjects had solid tumor cancer diagnosis
including breast, colon and lung cancers, and were on non-hormonal oral
chemotherapeutic agents. Subjects had a touch-tone phone, no hearing deficits that
interfered with using a telephone, understood English, had no cognitive deficits as
evaluated by an on-site nurse, were willing to complete eight automated phone contacts
requesting information on symptom severity and medication adherence, and phone
contacts for nurse interventions for management of severity of symptoms and adherence
to oral chemotherapeutic agents, and were not diagnosed with an emotional or
psychological disorder under the care of a psychiatrist or psychologist. This pilot study
began with trained nurse recruiters identifying subjects and explaining the study. All
enrolled subjects received a copy of the Symptom Management Toolkit (SMT) from the
nurse recruiter, prior to leaving the clinic.

Instruments and Measures
Symptom Experience Inventory. The cancer symptom inventory, developed by this
research team, has been used in previous work.2, 3 Fifteen prevalent symptoms
associated with patients undergoing chemotherapy were examined. Patients were asked
if, within the past 7 days, they had experienced each symptom (yes/no) and, if so, to rate
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the severity on a 0 to10-point scale of how severe this symptom was and the extent the
symptom disrupted or caused limitations in their regular daily activities.

Depression. The CESD-20 depression scale is a widely used measure of depressive
affect for non-psychiatric populations.4,5 This measure has established psychometric
properties (coefficient alpha .89).2

Short Form-12.The SF-12 functional ability scale is a widely used measure of an
individual’s ability to function. This measure has sound psychometric properties (alpha
.92) in this research.

Utilization and Services. The study focused on the use of increased physician oncology
visits, hospitalizations, and emergency room visits during the study time period (8
weeks).

Beliefs About Medications; Satisfaction with Information on Oral Agents. Adherence to
oral agents is related to patients’ beliefs about the amount of information they have
received regarding their prescribed oral chemotherapy agent, including actions and
possible side effects, and with beliefs about concerns and necessity of specific
medications.6,7 The concerns and necessities subscales to be used were developed
from social cognitive8 and self-regulatory frameworks and represents potential costs
associated with symptoms and side effects.

The Satisfaction with Information about Medicines Scale (SIMS)9 evaluates patients’
perceptions of the quality of medication information that they have received. Two
subscales related to medications were used. Internal consistency, measured by
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coefficient alpha for the oncology sample, was .81 and .80 respectively; test-retest
reliability produced statistically significant correlations over time for each subscale; and
validity as tested against adherence was significant.

The second set of measures, Beliefs about Medicines Questionnaire (BMQ), assesses
patients’ beliefs regarding the necessity and concerns about their medications.10 Specific
items were tested across multiple samples of patients with different diseases. The
specific “necessity” and “concerns” subscales had internal consistency scores in the mid
70’s. Specific necessity correlated highly with adherence levels and concerns subscale
correlated with poor adherence. This measure, while not tested on cancer patients, has
strong psychometric properties and taps dimensions specific to the oral agents
prescribed in this study.

Out-Of-Pocket Costs. At intake and 10 weeks, patients were asked how much they paid
out-of-pocket (OOP) for their oral chemotherapy agents. These costs were then prorated over the numbers of pills purchased. The cost of the drugs was obtained from the
pharmacies, and co-pays were determined for each oral agent.

Adherence with Oral Agents. Patient adherence to their oral chemotherapeutic agents
was measured from multiple perspectives. Medical record audits were performed at the
time the patient consented, (identify the site of cancer, stage, the name of the oral agent,
the number of pills prescribed per day, times per day, number of pills per time, and the
interval between doses) and at the end of the study (change in dose, pills per day
intervals and dose delays, stoppages and the dates of each). Patient report of
adherence was obtained from the intake and 10 week interviews and at each of the 8
AVR calls. During the intake and 10 week interviews, patients were asked to identify the

6
name of their oral agent, number of pills to be taken in AM and PM, and the number of
days or weeks on and off pills per month or cycle. At each weekly AVR call, the system
asked for the number of pills the patient took in the past seven days. If the patient
reported a number different than programmed initially, the nurse intervener was sent an
email notifying her of a discrepancy.

Specialty and Regular Pharmacy Report. Following the 10-week interview, the patient’s
pharmacy was contacted with the patient’s permission and a report requested with fill
and refill information for the oral chemotherapeutic agent(s), specifically detailing the
number of pills dispensed to the patient during the study.

Calculation of Adherence Measures. The nurse intervener made the following
comparisons: 1) compared information from intake audit with data collected during the
intake interview on medications to assess the baseline level of adherence. This note was
placed in the electronic intervention file for each patient and anchored decisions
regarding adherence at subsequent calls. 2) Following each weekly call, patients
reporting pill counts less or more than originally prescribed, received a call from the
nurse intervener to confirm non-adherence and to provide an intervention when needed.
If the patient reported a dose adjustment adjusted by the oncologist, then the nurse
determined the reason for the adjustment and, if it was due to a symptom, assisted the
patient to manage the symptom. At that point the intervention was logged as symptom
assistance.

At the end of the 10-week study, the on-site nurse recruiter audited the medical chart,
recorded dose changes, delays, reductions, stoppages, and toxic side effects and
provided the audit results to MSU. This information was compared as follows: a) the
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weekly AVR patient reports of pill counts with the dose from the medical record adjusted
for delays, interruptions, and stoppages; b) the Intake and 10-week interviews data were
paired with the record data on dosing and changes as of the date of the interview; c)
each of these indicators was paired at each time point against the availability of pills to
the patient based upon the prescriptions filled and number of pills obtained per script.
The pilot study collected an array of adherence measures for each patient.

Patient Acceptability and Satisfaction. Patient acceptability of the intervention was
measured by number of AVR calls missed that were not related to hospitalization or poor
health. Telephone hang-ups were counted and where in the course of the AVR script
they occurred – symptom management or adherence. Second, acceptability was
assessed by the proportion of nurse calls that were accepted and completed for
management of symptoms and for assistance with adherence (nurse-related
acceptance). Satisfaction with the AVR system and Symptom Management Toolkit
(SMT) was measured using a short satisfaction instrument designed especially to
capture patients’ level of satisfaction with the AVR system that was used in the previous
RCT. A series of satisfaction items describing dimensions of patients’ satisfaction with
the nurse calls were used to examine adherence. This satisfaction measure was used in
a previous trial of the AVR. Psychometrics for this instrument were found to be
acceptable (alpha greater than .65) as assessed during the course of the pilot study.

Procedures
The pilot study began with trained nurse recruiters identifying patients and explaining the
study. All enrolled patients received a copy of the SMT from the nurse recruiter, prior to
leaving the clinic. Enrolled patients then received an intake interview, eight AVR calls, an
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exit interview and nurse intervention calls when the AVR system indicated nonadherence and/or symptom severity of >4 for three consecutive weeks.

Interviews
Intake and Exit Interviews were conducted by experienced interviewers and entered onto
a Computer Assisted Telephone Interview system. Sociodemographic information was
collected on the intake interview. Patient intake and exit interviews included:
measurements of adherence, compliance with oral medications, oral chemotherapy pill
beliefs, health conditions, symptoms, the CESD, the SF-12, beliefs, and service
utilization.

Data were collected at all eight AVR contacts by the investigation software. The AVR
system used a pleasant female voice that asked to speak when that person would be
available or the system called two more times at 40 minute intervals and repeated this
process the following day beginning at the scheduled time. If no one answered on the
second week, then the project manager contacted the patient directly.

The study patients received eight weekly calls from the AVR System to assess severity
of 15 symptoms, and oral chemotherapy agent(s) adherence. At each contact, patients
were asked to enter their personal identity number (PIN) for identification. If incorrect or
forgotten, then someone from the staff called the patient and reminded them of their PIN
so that calls could take place. At the first and all subsequent calls, patients were asked
about the number of oral cancer pills they were prescribed and had actually taken in the
past week. Then patients were queried as to the severity of each of 15 symptoms;
asking them to indicate on a scale from 0 (not present) to 10 (worst severity possible),
“currently how severe is your symptom?” At the end of the call the system indicated the
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symptoms that patients identified with a severity of 4 or higher and asked them to read
those sections of the SMT for each symptom. Subsequent calls began with questions on
the number of pills taken and then a review of those symptoms scored at a 4 or higher at
the previous session then followed. Patients were asked: at the last call, you indicated
(the voice states the symptom) symptom was a problem for you at a moderate or higher
level; were you able to read the information in the SMT? If yes, how helpful was this
information for managing this symptom?

Once all symptoms above threshold from the previous call were reviewed and the value
of the SMT scored, the program asked the current adherence and symptom severity
questions, severity of current symptoms rated, and the SMT assigned. To this script we
added questions to patients regarding the numbers of pills they had taken in the past
week and the number of pills prescribed. If the patient reported anything other than the
exact number of chemotherapy pills prescribed, a nurse would review the pill count with
the patient’s prescription and a calendar indicating cycle information which included onoff days or weeks; and if the count appeared non-adherent the patient was called by the
nurse to confirm an accurate pill count. Many times during this pilot patients either
counted their pills incorrectly or pressed the wrong telephone keys. As a final means of
confirming patient-adherence with the physicians prescribed dosage of oral
chemotherapy, a medical record audit was conducted including pharmacy fill and refill
information.

Nursing Interventions
Study patients reporting symptom severity at their weekly AVR calls were encouraged to
use the SMT. In addition, if the patient reported anything less than 100% adherence
through the weekly AVR calls or severity of one or more symptoms at a >4 for three
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consecutive weeks, a nurse contacted the patient by telephone to confirm nonadherence and/or provided evidence-based nursing intervention for adherence and/or
management of symptoms. Preliminary work using the AVR call system was completed
by the research team comparing a nurse administered telephone intervention to reduce
symptom severity among advanced cancer patients undergoing chemotherapy (primarily
infusion). The results of the previous work indicated that both the AVR alone and with
nursing intervention decreased symptom severity.11,12

Nursing interventions were based on Cognitive Behavioral Theory. The domains for the
nursing interventions include: fostering self care behaviors, providing information about
oral agents, problem solving for symptoms or adherence, providing support, coaching
and counseling, communication with providers, and decision making; all to enhance
tailored symptom management and adherence behaviors. The nurse intervention
strategies were evidence-based for each symptom or adherence. Strategies on
symptoms have been tested in three previous NCI funded RCTs and were used to form
a plan of care for the patient. Symptom Management Toolkit (SMT) is a supplemental
information source given to all patients. It is organized into a Frequently Asked
Questions format and covers what is needed to manage side effects from treatment and
the sequelae of cancer. Questions include: What is the symptom; How do people
describe it; What causes it; What do people do to manage it; Where can they find
additional information; and, Where can they find additional information? This guide has
been used in several RCT’s and is well accepted by patients. The reading level is 6th-7th
grade.

Results
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This pilot study examined the ability to monitor patients for adherence to oral
chemotherapeutic agents, using an AVR program and a nurse administered telephone
intervention to reduce symptom severity among advanced cancer patients undergoing
chemotherapy. A total of 30 patients agreed to participate in the study, signed informed
consents and completed the recruitment process. Eight withdrew from the study (26.7%)
for various reasons (predominately health related).

Sociodemographic Characteristics
The sociodemographics of the sample are presented in Table 1. The mean age of the
subjects was 59.93 years (SD = 12.03), and 94% were female. Sixty-three percent of the
subjects had at least some college education, 90% were white, and 80% were married.
Breast cancer was the most common diagnosis and 77.67% were on a single oral
chemotherapeutic agent, with varied lengths of time, from 1 to 8 months. No significant
differences between the groups at baseline were found for gender, age, race, or
ethnicity, education, marital status or type of cancer, and in some instances, the sample
size was too small to test equivalency.

Non-adherence
The percent of missed pills was calculated weekly using the number of pills confirmed,
divided by the number of pills prescribed. Seven out of 30 study subjects, or 23%, had
confirmed non-adherence over the eight week study period. The most common reported
reason for non-adherence was ‘forgot’ to take the pills, which occurred with 5 subjects.
One subject could not identify a reason of non-adherence. Six of the non-adherent
patients missed pills one time out of the 8 weeks, or 13% of the time the subject missed
their full number of prescribed pills. One patient missed 4 out of 8 weeks, or 50% of the
time the subject missed their full number of prescribed pills. Of the six subjects who
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missed pills they took between 86% and 93% of their weekly pills. Of the subject that
missed pills for 4 out of 8 weeks, the subject reported taking 90% of the prescribed pills
on average.

Association between Symptom Management and Non-Adherence
To check the effect of symptom management, we used paired t-test to see how
symptom severity changed before and after AVR intervention. Sum of symptom severity
at intake was treated as symptom severity before intervention and at exit as after
intervention. Overall, for 22 patients who finished intake, AVR intervention and the exit
interview, their average sum of symptom severity decreased 4.35 with p-value 0.21
(which means not a significant difference between symptom severity before AVR
intervention and after AVR intervention). When we compared the symptom severity
before intervention and after intervention for those who stayed in the pilot study by their
adherence status, there existed a marginal decrease in severity for non-adherence (pvalue = 0.04) as shown in Table 2.

Association between Number of Oral Agents and Adherence
To understand if two oral agents influence non-adherence more than one oral agent, a
comparison was conducted (see Table 3). 77% of the study subjects were on one oral
agent and 23% were on two oral agents. 17 study subjects, or 57%, were on concurrent
intravenous chemotherapy. 75% were adherent on single oral agent compared to 86% of
the subjects who were on two oral agents. In addition, eight study subjects, or 27%,
discontinued their oral agents sometime during the study. Five study subjects or 17%
had a physician initiated dosage change (increase or decrease in dosage).

Nurse Interventions
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During the pilot study, a specialty trained nurse intervener provided patient-centered
personalized interventions via phone calls for patients that had symptom severity of 4 or
higher for three consecutive weeks and/or to patients that had non-adherence of less
than 100%. (See Table 4)

Satisfaction Questionnaires
Satisfaction questionnaires were administered to all subjects following the 10-week
survey. 54% of the study subjects completed the satisfaction questionnaire, for a total of
77% (see Table 5). Of the 17 subjects that completed the satisfaction questionnaire, 12
subjects, or 70% were adherent, and 5 subjects, or 30% were non-adherent.

Overall, 100% of the subjects who completed the survey were either very satisfied or
satisfied with the AVR for monitoring symptoms. Of those, 76% used the SMT with a
high rate of referral to the appropriate section of the toolkit to manage a symptom. Of
those who were contacted by a study nurse, 65% reported help from the nurse with
symptoms and 100% reported help from the nurse with non-adherence. In summary,
60% felt the intervention was helpful, while 30% felt it was both burdensome and helpful,
and 10% felt it was not helpful. Of those, 88% would recommend the intervention for
symptom management and 53% for adherent to medications. Of the two subjects who
were non-adherent and completed the survey, neither felt it was helpful with promoting
adherence to the oral chemotherapy medication and they were non adherent for reasons
of forgetting and missing pills.

Discussion
The primary aim of this study was to determine the feasibility of monitoring and providing
interventions to patients with breast, colon, or lung cancer on non-hormonal
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chemotherapeutic agents sing and AVR system and nurse intervener. The results
support such feasibility, as the system was easy to use, easy to learn, and captured the
clinical information from patients in their homes.

A majority of patients experienced symptoms that were severe enough to generate
referral to the SMT and nurse interventions, and non-adherence that prompted nurse
interventions, as well as an alert to their clinician. Fatigue and pain were the most
frequently occurring symptoms with symptom severity of >4 for three consecutive weeks.
Fatigue was a side effect of the oral agents that patients were on while on this study.
Other less frequent symptoms warranting nurse intervention included lack of appetite,
numbness and tingling, sleep disturbances and distress, which were also side effects
from their oral agents (see Table 4). The secondary aims of this study were to determine
if non-adherence can be defined and measured, to examine the relationship between
symptom severity and adherence, and to compare and contrast the adherence group
with the non-adherence group. The data presented here supports that contention.

First, and most importantly, non-adherence was defined and measured. Studies indicate
that self-report measures, although the most common and easiest to use, have varied
concordance with other means of measuring adherence. 13 Self-reporting using the AVR
system with follow-up from a nurse from the study would eliminate some of the inherent
hesitancy a patient might have in admitting non-adherence to the clinicians that
prescribed the medication. The patients who reported non-adherence through the AVR
were confirmed when reported to the nurse. The research oncology nurse reviewed the
enrollment documents, prior to each patient-call. The enrollment documents included
oral agent information such as a calendar indicating when the patient was to be and off
oral agent(s). The nurse asked each patient that reported non-adherence why they
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missed their pills and again as is consistent with other studies the most common reason
for missed doses was forgetting.14 For the patient who reporting ‘out of drug’, we
confirmed drug unavailability through a pharmacy audit. This appeared to be consistent
with other studies, where the undersupply of cancer drugs appeared to be as common
(14%) as the undersupply of other drugs.15

Second, the AVR System was tested and found to work effectively and efficiently.
Automated telecommunication systems have shown in published studies to improve
medication adherence 16 however to our knowledge this is the first time the AVR system
has been used to explore how it might improve adherence to oral chemotherapeutic
agents with cancer patients. We understand that one study showed that simple
telephone contacts from the clinician’s office by a non-nurse did not significantly improve
adherence. 17 However, the structured eight-week AVR system plus individualized
nursing calls may more closely mirror the published work of Burke 18 and Kim 19 with the
success of using behavioral interventions for improved adherence.

Finally, a beginning exploration of the relationship between symptom severity,
adherence, and beliefs about medications occurred. Addressing the barriers to treatment
adherence is complex and most likely patients have multiple reasons for non-adherence
to oral agents. The severity of symptoms from cancer and the side effects of the oral
agents may be one of the reasons. Studies of cancer and non-cancer diseases indicate
that patients decrease adherence as symptoms and medication side effects occur.

20

In

this pilot study, no such effect was observed, most likely due to the small sample size.

Although it was beyond the scope of this pilot to evaluate the effectiveness of the AVR
system and nurse calls as an intervention to improve adherence to oral
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chemotherapeutic agents, we did learn from our participants that our calls were
perceived as ‘caring.’ One patient reported that no one at the clinic ever asked her if she
was taking her pills and therefore she thought she was taking ‘enough’ although she
missed four doses over the eight week period. Treatment adherence may be improved if
clinicians directly ask patients about their adherence, as well as review the importance of
taking oral medications as directed and the possible effect of adherence on their
response to treatment.17-19, 21, 22

Future studies on interventions for non-adherence include asking the patient if they are
taking their pills exactly as prescribed at each office visit. Perhaps this question will elicit
a similar response to clinicians asking patients about their smoking cessation, where just
asking the question at each visit will improve the outcome, in this case, improve
adherence.

The level of satisfaction with and acceptability of the AVR was high. The technique,
voice, and duration were acceptable to subjects and generally did not pose any technical
difficulty. The few technical problems that were encountered were resolved in a timely
fashion. Subjects offered suggestions on ways to expand and enhance the system that
have already been incorporated into future versions.

With these revisions, the next research step, which has been initiated, is to test the value
of the AVR symptom assessment and management system in improving adherence to
oral chemotherapy agents. This study is ongoing and will further evaluate the
relationship between symptom management and adherence. Before an electronic
system can be incorporated into clinical care, it is essential to demonstrate that these
systems are reliable, that they improve care, and that they are cost-effective.
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Tables/Figures:

Table 1 Sociodemographic Characteristics and Cancer

Adherence (n=23 or 77%)
Demographic Characteristic

n (%)

Non-adherence (n=7 or 23%)
n (%)

Gender
Male
Female

2 (8.7)
21 (91.3)

7 (100.0)

Age
21-40

1 (4.4)

-

41-60

11 (47.8)

5 (71.4)

61-70

4 (17.4)

2 (28.6)

>71

7 (30.4)

-

Race or ethnicity
White

22 (95.7))

5 (71.4)

Black

1 (4.4)

1 (14.3)

Asian/Other

-

1 (14.3)

Education
High school graduate

10 (43.5)

1 (14.4)

Some college

5 (21.7)

3 (42.3)

College graduate

7 (30.4)

3 (42.3)

Some post college

1 (4.4)

-

Never married

-

2 (8.7)

Married

19 (82.6)

5 (71.4)

Marital status

Divorced/Separated

2 (8.7)

-

Widowed

2 (8.7)

-

Type of Cancer
Breast Cancer

17 (74.0)

7 (100.0)

18
Colon Cancer

3 (13.0)

-

Lung Cancer

3 (13.0)

-
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Table 2. Summed Severity Scores on Intake and Exit Interviews

Adherence (n=23 or 77%)
Mean (SD)

Non-adherence (n=7 or 23%) T-value
Mean (SD)

Clinical Characteristics

P-value

for group
difference

Summed symptom severity scores
Intake Interview

25.91 (16.69)

24.57 (15.67)

0.20

0.85

Exit Interview

27.38 (20.14)

14.86 (16.0)

1.42

0.17

SD: standard deviation.
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Table 3. Oral Agents and Months on Oral Agent(s)

Adherence (n=23 or 77%)
n

%

Non-adherence (n=7 or 23%)
n

Type of single oral agent
Capecitabine (Xeloda)

12 (70.6)

5 (83.3)

Cyclophosphamide (Cytoxan)

2 (11.8)

-

Erlotinib (Tarceva)

3 (17.7)

-

Lapatinib (Tykerb)

-

1 (16.7)

Type of multiple oral agent
Cyclophosphamide+Methotrexate

2 (33.3)

-

Capecitabine+Lapatinib

4 (66.7)

1 (100.0)

1 month

8 (38.1)

3 (42.9)

2 months

5 (23.8)

1 (14.3)

3 months

1 (4.8)

-

4 months

1 (4.8)

-

5 months

2 (9.5)

-

6 months

3 (14.3)

1 (14.3)

Months on oral agent

7 months
8 months

1 (4.8)

2 (28.6)
-

%
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Table 4. Number of Patients with Symptoms above Threshold (>=4), AVR Interventions,
Nurse Interventions, Resolution of Symptom by Adherent and Non-adherent Patients

Number of

Number of

Number of

Number of

Total Number

Patients

Patients

Patients

Patients

of Patients

with Symptom

with Symptom

Referred to

Referred to

with Resolved

Severity >=4 at

Severity Resolved

Nurse

Nurse with

Symptoms by

N

Resolved Symptom

End of Study

by End of Study

N (%*)

rd

First Contact

by 3 week

N (%)

N (%*)

Symptoms

N (%**)

Fatigue

12 (40.00)

4 (33.33)

8

2 of 8 (25.00)

6 of 11 (50.00))

Pain

11 (36.67)

2 (18.18)

9

1 of 9 (11.11)

3 of 11(27.27)

Pain/redness

11 (36.67)

8 (72.73)

3

1 of 3 (33.33)

9 of 11 (81.82)

Nausea/vomiting

3 (10.00)

1 (33.33)

2

1 of 2 (50.00)

2 of 3 (66.67)

Lack of appetite

8 (26.67)

4 (50.00)

4

2 of 4 (50.00)

6 of 8 (75.00)

Constipation

5 (16.67)

2 (40.00)

3

1 of 3 (33.33)

3 of 5 (60.00)

Skin rash

6 (20.00)

5 (83.33)

1

1 of 1 (100)

6 of 6 (100)

Numbness/tingling

9 (30.00)

5 (55.56)

4

1 of 4 (25.00)

6 of 9 (66.67)

Sleep disturbance

4 (13.33)

0

4

2 of 4 (50.00)

2 of 4 (50.00)

Sore mouth

5 (16.67)

4 (80.00)

1

0

4 of 5 (80.00)

Distress

6 (20.00)

2 (33.33)

4

2 of 4 (50.00)

4 of 6 (66.67)

Dyspnea

3 (10.00)

1 (33.33)

2

0

1 of 3 (33.33)

Diarrhea

7 (23.33)

4 (57.14)

3

0

4 of 7 (57.14)

Fever

1 (3.33)

1 (100)

0

0

1 of 1 (100)

Swelling

4 (13.33)

1 (25.00)

3

1 of 3 (33.33)

2 of 4 (50.00)

*Percentage based on number of patients with symptoms above threshold at first contact
** Percentage based on number of patients referred to nurse intervention
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Table 5. Satisfaction with the AVR, SMT, and Nurse Administered Interventions

Adherence (n=12 70.58%) Non-adherence(n=5 29.42%)
Satisfaction Questions

n (%**)

n (% **)

9 (75.00)

1 (20.00)

AVR for monitoring symptoms
Very satisfied
Somewhat satisfied
Just right

-

2 (40.00)

3 (25.00)

2 (40.00)

Yes

9 (75.00)

4 (80.00)

No

3 (25.00)

1 (20.00)

Strongly agree

2 (16.67)

1 (25.00)

Agree

4 (33.33)

3 (75.00)

Neither agree or disagree

3 (25.00)

-

Disagree

3 (25.00)

-

Strongly agree

2 (16.67)

-

Agree

3 (25.00)

2 (50.00)

Neither agree or disagree

5 (41.66)

2 (50.00)

Disagree

2 (16.67)

-

Strongly agree

3 (30.00)

-

Agree

3 (30.00)

Neither agree or disagree

2 (20.00)

Use of SMT

Telephone referred to appropriate
Section of SMT to manage symptom *

Telephone helped patient be more independent
for symptom management *

The MSU nurse helped with symptoms *

3 (75.00)
-
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Disagree

2 (20.00)

1 (25.00)

The MSU nurse helped with adherence *
Strongly agree

1 (20.00)

Agree

2 (40.00)

-

Neither agree or disagree

1 (20.00)

-

Disagree
Strongly disagree

1 (20.00)

-

2 (100)
-

Overall AVR and Oral Chemotherapy
Monitoring system
Burdensome

-

2 (40.00)

Both burdensome and helpful

5 (41.67)

Helpful

7 (58.33)

3 (60.00)

10 (91.91)

4 (80.00)

1 (9.09)

1 (20.00)

Yes

7 (58.33)

2 (40.00)

No

5 (41.67)

3 (60.00)

-

Recommend AVR to Oncologist to
Monitor symptoms *
Yes
No

Recommend AVR to Oncologist to
Remind to take pills

* Some respondents did not complete the entire survey.
** Percentage totaled for each adherence and non-adherence group.
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Key Words: Oral Chemotherapy. Symptom management. Adherence.
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